Olivier Kreis

Title: Innovations in Protein Modification by Olivier Kreis

Introduction

Olivier Kreis is a notable inventor based in Frick, Switzerland. He has made significant contributions to the field of protein modification, particularly through his innovative patent that focuses on site-specific conjugation to antibody lysine residues. His work is essential for advancing therapeutic applications in biotechnology.

Latest Patents

Kreis holds a patent titled "Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution." This patent describes a powerful and versatile strategy for the controlled modification of proteins under physiological conditions. The method utilizes solid-phase microbead-immobilization to efficiently attach various functional molecules to proteins of therapeutic relevance, including scFV, Fab-fragment, and antibodies. The immobilized MTG enzyme demonstrates enhanced selectivity towards specific residues, ensuring effective conjugation.

Career Highlights

Olivier Kreis is affiliated with the Paul Scherrer Institut, where he continues to explore innovative approaches in protein engineering. His research has led to the generation of dual site-specifically conjugated IgG1 antibodies, showcasing his expertise in the field. His work is characterized by a commitment to advancing biotechnological applications that can have a significant impact on therapeutic development.

Collaborations

Kreis collaborates with esteemed colleagues such as Philipp Rene Spycher and Martin Behe. Their combined efforts contribute to the advancement of research in protein modification and its applications in medicine.

Conclusion

Olivier Kreis's innovative work in protein modification through site-specific conjugation represents a significant advancement in biotechnology. His contributions are paving the way for new therapeutic strategies that can enhance the efficacy of antibody-based treatments.